Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Biotech Stocks Technical Study -- Orexigen Therapeutics, Celgene, PDL BioPharma, Amarin, and Synergy Pharma18 Mar 2015, 7:01 amLONDON, March 18, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Celgene Corporation (NASDAQ: CELG), PDL BioPharma Inc....
Pre-Market Most Active for Mar 16, 2015 : AMRN, SLXP, TVIX, RDS/B, FXCM, BAC, XIV, QQQ, AAPL, LTM, MT, NOK16 Mar 2015, 7:37 amPre-Market Most Active for Mar 16, 2015 : AMRN, SLXP, TVIX, RDS/B, FXCM, BAC, XIV, QQQ, AAPL, LTM, MT, NOK
Amarin up premarket12 Mar 2015, 6:35 amAmarin (NASDAQ: AMRN ) is up 16% premarket on increased volume. H.C. Wainwright analyst Andrew Fein upgraded the stock to "Buy" with a $10 price target. The consensus analyst rating on the stock is "Hold" with a $6 target.
Earnings Reaction History: Amarin Corp., 42.9% Follow-Through Indicator, 6.6% Sensitive3 Mar 2015, 1:25 pmEarnings Reaction History: Amarin Corp., 42.9% Follow-Through Indicator, 6.6% Sensitive
What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog2 Mar 2015, 11:00 amGeron Corporation (GERN) is set to report fourth quarter 2014 results on Mar 3 after the market closes.
Intercept Pharmaceuticals (ICPT): Will It Miss Q4 Earnings? - Analyst Blog28 Feb 2015, 6:01 pmIntercept Pharmaceuticals, Inc is slated to report its fourth-quarter 2014 results on Mar 2, 2015.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog27 Feb 2015, 2:22 pmArena Pharmaceuticals (ARNA) is scheduled to report fourth-quarter 2014 results on Mar 2.
Will Endo Internationa's (ENDP) Beat on Earnings in Q4? - Analyst Blog27 Feb 2015, 2:18 pmEndo International, Inc. (ENDP) is scheduled to report its fourth-quarter and full-year 2014 results on Mar 2, 2015.
Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog27 Feb 2015, 11:30 amMylan (MYL) is set to report fourth quarter 2014 results on Mar 2 before the market opens.
Will Stratasys (SSYS) Disappoint this Earnings Season? - Analyst Blog27 Feb 2015, 9:10 amStratasys Ltd. (SSYS) is set to report fourth-quarter 2014 results on Mar 2.